<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Iobitridol</id>
	<title>Iobitridol - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Iobitridol"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Iobitridol&amp;action=history"/>
	<updated>2026-04-27T01:02:51Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Iobitridol&amp;diff=5368623&amp;oldid=prev</id>
		<title>Prab: Undo revision 5368290 by Prab (talk)</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Iobitridol&amp;diff=5368623&amp;oldid=prev"/>
		<updated>2024-03-06T04:13:23Z</updated>

		<summary type="html">&lt;p&gt;Undo revision 5368290 by &lt;a href=&quot;/wiki/Special:Contributions/Prab&quot; title=&quot;Special:Contributions/Prab&quot;&gt;Prab&lt;/a&gt; (&lt;a href=&quot;/wiki/User_talk:Prab&quot; title=&quot;User talk:Prab&quot;&gt;talk&lt;/a&gt;)&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[File:Iobitridol.png|thumb|Iobitridol]]&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Iobitridol&amp;#039;&amp;#039;&amp;#039; stands as a vital nonionic [[contrast medium]] utilized in the field of radiological imaging, particularly in X-ray procedures. The molecule&amp;#039;s efficiency and utility are attributable to its three iodine atoms, which make up 45.6% of its molecular mass.&lt;br /&gt;
=== Chemical Composition and Properties ===&lt;br /&gt;
At the core of Iobitridol&amp;#039;s efficacy is its inherent molecular structure, fortified by the presence of three iodine atoms. These iodine atoms contribute to a significant portion of its molecular weight, accounting for almost half at 45.6%&amp;lt;ref&amp;gt;Thomsen, H. S., &amp;amp; Morcos, S. K. (2003). Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. &amp;#039;&amp;#039;British Journal of Radiology&amp;#039;&amp;#039;, 76(908), 513-518.&amp;lt;/ref&amp;gt;. The nonionic nature of Iobitridol is contrasted by its water solubility, achieved through several hydroxyl (-OH) groups.&lt;br /&gt;
=== Commercial Formulations ===&lt;br /&gt;
One of the prominent commercial solutions containing Iobitridol is &amp;#039;&amp;#039;&amp;#039;Xenetix 300&amp;#039;&amp;#039;&amp;#039;, a product of Guerbet based in Roissy, France. This formulation offers Iobitridol at a concentration of 300 mg iodine/ml. The recommended dosage for optimal efficacy spans from 1.1 to 2.8 ml/kg of body mass, which translates to an iodine concentration of 0.33 to 0.84 g/kg within the human body&amp;lt;ref&amp;gt;Spinazzi, A., Lorusso, V., Pirovano, G., &amp;amp; Taroni, P. (2002). Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. &amp;#039;&amp;#039;Academic Radiology&amp;#039;&amp;#039;, 9, S305-S313.&amp;lt;/ref&amp;gt;.&lt;br /&gt;
=== Applications and Metabolism ===&lt;br /&gt;
Upon intravenous administration, Iobitridol undergoes renal filtration, ensuring its prompt and efficient elimination from the human system. Beyond X-ray imaging, its applications are diverse:&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Arthrography:&amp;#039;&amp;#039;&amp;#039; Iobitridol aids in the visualization of joint spaces.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Hysterosalpingography:&amp;#039;&amp;#039;&amp;#039; The contrast agent is utilized to fill and delineate the uterus and fallopian tubes, assisting in the evaluation of potential pathologies or anatomical anomalies.&lt;br /&gt;
Its pharmacokinetic properties are optimized for safety, minimizing the risk of potential adverse reactions.&lt;br /&gt;
=== Conclusion ===&lt;br /&gt;
Iobitridol has carved out a significant niche in the realm of radiological imaging, offering enhanced visualization across a range of diagnostic procedures. With its unique balance of nonionic yet water-soluble properties, and its optimized commercial formulations, it stands as a testament to the advances in contrast media technology.&lt;br /&gt;
== References ==&lt;br /&gt;
* Thomsen, H. S., &amp;amp; Morcos, S. K. (2003). Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. &amp;#039;&amp;#039;British Journal of Radiology&amp;#039;&amp;#039;, 76(908), 513-518.&lt;br /&gt;
* Spinazzi, A., Lorusso, V., Pirovano, G., &amp;amp; Taroni, P. (2002). Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. &amp;#039;&amp;#039;Academic Radiology&amp;#039;&amp;#039;, 9, S305-S313.&lt;br /&gt;
{{pharmacology-stub}}&lt;br /&gt;
{{Contrast media}}&lt;br /&gt;
[[Category:Radiocontrast agents]]&lt;br /&gt;
[[Category:Organoiodides]]&lt;br /&gt;
[[Category:Benzamides]]&lt;br /&gt;
[[Category:Anilides]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>